A vaccine adjuvant and immunogenic composition may be described herein. The vaccine adjuvant may comprise cell wall fragments of the genus Mycobacterium, and more particularly, of M. avium. The immunogenic composition may include the vaccine adjuvant conjugated to an antigen. For example, cell wall fragments of M. avium (herein also referred to as MAF) may be conjugated to an antigen targeting Gonadotropin releasing hormone (GnRH). The MAF-antigen conjugate may be delivered for the purposes of treatment through one of several methods, including intramuscular injection, naso-pharyngeal, or oral.

A vaccine adjuvant and immunogenic composition may be described herein. The vaccine adjuvant may comprise cell wall fragments of the genus Mycobacterium, and more particularly, of M. avium. The immunogenic composition may include the vaccine adjuvant conjugated to an antigen. For example, cell wall fragments of M. avium (herein also referred to as MAF) may be conjugated to an antigen targeting Gonadotropin releasing hormone (GnRH). The MAF-antigen conjugate may be delivered for the purposes of treatment through one of several methods, including intramuscular injection, naso-pharyngeal, or oral.

The application describes the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.

The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.

The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.

An antibody-conjugated nanoparticle, 50 to 1000 nm in size, containing an anti-Mullerian hormone receptor II (AMHRII) antibody that is conjugated to a nanocomplex formed of a lipid-based delivery agent and a cytotoxin, the delivery agent and the cytotoxin being non-covalently bonded to each other. Also disclosed are a method of preparing such an antibody-conjugated nanoparticle and use thereof for inducing sterilization in a subject and for treating an AMHRII-associated condition.

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.

Methods of using 7,11-dimethyl-17-hydroxy-4-estren-3-one bucyclate (I) and 7,11-dimethyl-17-hydroxyestr-4-en-3-one 17-undecanoate (II) ##STR00001##
for various hormonal therapies, dosage forms comprising 7,11-dimethyl-17-hydroxy-4-estren-3-one bucyclate and 7,11-dimethyl-17-hydroxyestr-4-en-3-one 17-undecanoate, and processes for their preparation.

The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception. ##STR00001##